Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q30/00—Commerce
- G06Q30/02—Marketing; Price estimation or determination; Fundraising
- G06Q30/0241—Advertisements
- G06Q30/0251—Targeted advertisements
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Application Number	Priority Date	Filing Date	Title
US201361802296P	2013-03-15	2013-03-15
US201361812678P	2013-04-16	2013-04-16
US201361829236P	2013-05-30	2013-05-30
US201361883186P	2013-09-26	2013-09-26
PCT/US2014/024746WO2014151006A2 (en)	2013-03-15	2014-03-12	Biomarkers and methods of treating pd-1 and pd-l1 related conditions

Publication Number	Publication Date
SG11201507333XAtrue SG11201507333XA (en)	2015-10-29

Family

ID=50391526

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201507333XASG11201507333XA (en)	2013-03-15	2014-03-12	Biomarkers and methods of treating pd-1 and pd-l1 related conditions
SG10201701380TASG10201701380TA (en)	2013-03-15	2014-03-12	Biomarkers and methods of treating pd-1 and pd-l1 related conditions

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SG10201701380TASG10201701380TA (en)	2013-03-15	2014-03-12	Biomarkers and methods of treating pd-1 and pd-l1 related conditions

Country Status (18)

Country	Link
US (2)	US11299544B2 (en)
EP (3)	EP3633377A1 (en)
JP (2)	JP6483082B2 (en)
KR (6)	KR20220053691A (en)
CN (3)	CN110079599B (en)
AU (5)	AU2014235453A1 (en)
BR (1)	BR112015023120A2 (en)
CA (2)	CA3180286A1 (en)
ES (1)	ES2761260T3 (en)
HK (1)	HK1212769A1 (en)
IL (3)	IL318611A (en)
MX (2)	MX374488B (en)
MY (2)	MY176706A (en)
NZ (3)	NZ751260A (en)
PL (1)	PL2972373T3 (en)
RU (1)	RU2701378C2 (en)
SG (2)	SG11201507333XA (en)
WO (1)	WO2014151006A2 (en)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG10202112838YA (en)	2008-04-09	2021-12-30	Genentech Inc	Novel compositions and methods for the treatment of immune related diseases
SG196798A1 (en)	2008-12-09	2014-02-13	Genentech Inc	Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3045918B1 (en)	2009-10-21	2017-12-06	The Scripps Research Institute	Method of using non-rare cells to detect rare cells
US9945862B2 (en)	2011-06-03	2018-04-17	Eisai R&D Management Co., Ltd.	Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US9308236B2 (en)	2013-03-15	2016-04-12	Bristol-Myers Squibb Company	Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
CA3180286A1 (en)	2013-03-15	2014-09-25	Genentech, Inc.	Biomarkers and methods of treating pd-1 and pd-l1 related conditions
PL3021869T3 (en)	2013-07-16	2020-11-16	F. Hoffmann-La Roche Ag	Methods of treating cancer using PD-1 axis binding antagonists and TIGIT inhibitors
US20160312295A1 (en)*	2013-12-17	2016-10-27	Merck Sharp & Dohme Corp.	Gene signature biomarkers of tumor response to pd-1 antagonists
EP3647324A1 (en)	2013-12-17	2020-05-06	F. Hoffmann-La Roche AG	Methods of treating cancers using pd-1 axis binding antagonists and taxanes
EP3084005A4 (en)*	2013-12-17	2017-08-02	Merck Sharp & Dohme Corp.	Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
TWI681969B (en)	2014-01-23	2020-01-11	美商再生元醫藥公司	Human antibodies to pd-1
TWI680138B (en)	2014-01-23	2019-12-21	美商再生元醫藥公司	Human antibodies to pd-l1
US10527624B2 (en)	2014-01-27	2020-01-07	Epic Sciences, Inc.	Circulating tumor cell diagnostics for prostate cancer biomarkers
EP3108246B1 (en)	2014-02-21	2019-10-09	Epic Sciences, Inc.	Methods for analyzing rare circulating cells
DK3309174T3 (en)	2014-07-11	2022-06-07	Ventana Med Syst Inc	ANTI-PD-L1 antibodies and diagnostic uses thereof
TW201614237A (en)*	2014-09-05	2016-04-16	Medimmune Ltd	Markers for identifying patients responsive to anti-PD-L1 antibody therapy
EP3191113B1 (en)	2014-09-11	2019-11-06	Bristol-Myers Squibb Company	Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-l1 protein/protein interactions
US9732119B2 (en)	2014-10-10	2017-08-15	Bristol-Myers Squibb Company	Immunomodulators
US20170242016A1 (en)*	2014-10-15	2017-08-24	Epic Sciences, Inc.	Circulating tumor cell diagnostics for therapy targeting pd-l1
US9856292B2 (en)	2014-11-14	2018-01-02	Bristol-Myers Squibb Company	Immunomodulators
AU2015346185A1 (en)	2014-11-14	2017-05-04	Liquid Genomics, Inc.	Use of circulating cell-free RNA for diagnosis and/or monitoring cancer
ES2744936T3 (en)*	2014-12-02	2020-02-26	Univ Tokyo	Method to evaluate the therapeutic effect of an antineoplastic agent that has an anti-CD4 antibody as active ingredient
RU2017123117A (en)	2014-12-09	2019-01-10	Мерк Шарп И Доум Корп.	SYSTEM AND METHODS FOR PRODUCING BIOMARKERS OF GENE SIGNATURES OF RESPONSE TO PD-1 ANTAGONISTS
US9861680B2 (en)	2014-12-18	2018-01-09	Bristol-Myers Squibb Company	Immunomodulators
US9944678B2 (en)	2014-12-19	2018-04-17	Bristol-Myers Squibb Company	Immunomodulators
US20180017568A1 (en)*	2015-01-29	2018-01-18	Konica Minolta, Inc.	Method for simultaneously analyzing blood cells having interactive molecules
US20160222060A1 (en)	2015-02-04	2016-08-04	Bristol-Myers Squibb Company	Immunomodulators
JP6885869B2 (en)	2015-02-26	2021-06-16	メルクパテントゲゼルシャフトミットベシュレンクテルハフツングＭｅｒｃｋＰａｔｅｎｔＧｅｓｅｌｌｓｃｈａｆｔｍｉｔｂｅｓｃｈｒａｅｎｋｔｅｒＨａｆｔｕｎｇ	PD-1 / PD-L1 Inhibitors for Treating Cancer
KR20240064733A (en)	2015-03-04	2024-05-13	머크 샤프 앤드 돔 코포레이션	Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
CA2978942A1 (en)	2015-03-13	2016-09-22	Cytomx Therapeutics, Inc.	Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US9809625B2 (en)	2015-03-18	2017-11-07	Bristol-Myers Squibb Company	Immunomodulators
SMT202000444T1 (en)	2015-03-23	2020-09-10	Jounce Therapeutics Inc	Antibodies to icos
WO2016168133A1 (en)	2015-04-17	2016-10-20	Merck Sharp & Dohme Corp.	Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
MX2017014381A (en)	2015-05-12	2018-03-02	Genentech Inc	THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER.
EP3708681A1 (en)*	2015-05-29	2020-09-16	F. Hoffmann-La Roche AG	Therapeutic and diagnostic methods for cancer
EP3763827A1 (en)*	2015-05-29	2021-01-13	F. Hoffmann-La Roche AG	Pd-l1 promoter methylation in cancer
WO2016200835A1 (en)*	2015-06-08	2016-12-15	Genentech, Inc.	Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
IL256245B (en)	2015-06-16	2022-09-01	Merck Patent Gmbh	Treatments that combine a pd-l1 antagonist
KR102705821B1 (en)	2015-06-16	2024-09-12	가부시키가이샤 프리즘 바이오랩	Anticancer drug
JP6896650B2 (en)	2015-06-17	2021-06-30	ジェネンテック，インコーポレイテッド	Treatment of Locally Advanced or Metastatic Breast Cancer Using PD-1 Axle Antagonists and Taxanes
WO2017024465A1 (en)*	2015-08-10	2017-02-16	Innovent Biologics (Suzhou) Co., Ltd.	Pd-1 antibodies
AU2016309356B2 (en)	2015-08-20	2021-06-24	Eisai R&D Management Co., Ltd.	Tumor therapeutic agent
US10647771B2 (en)	2015-09-21	2020-05-12	Merck Sharp & Dohme Corp.	Antibody that binds to human programmed death ligand 2 (PD-L2) and uses thereof
JP6831112B2 (en)*	2015-10-15	2021-02-17	国立大学法人京都大学	Biomarkers for predicting the efficacy of PD-1 pathway inhibitors
EP3365372A1 (en)	2015-10-22	2018-08-29	Jounce Therapeutics, Inc.	Gene signatures for determining icos expression
US20190085401A1 (en)*	2015-10-27	2019-03-21	Pharmassist Ltd	Method for the quantification of pd-l1 expression
SG11201803009VA (en)	2015-11-02	2018-05-30	Five Prime Therapeutics Inc	Cd80 extracellular domain polypeptides and their use in cancer treatment
CN109608544B (en)	2015-11-17	2022-09-16	苏州盛迪亚生物医药有限公司	PD-L1 antibody, antigen binding fragment thereof and medical application thereof
US20180364240A1 (en)*	2015-12-10	2018-12-20	Medimmune, Llc	Methods for treatment and selection of patients responsive to immune mediated cancer therapy
BR112018012801B1 (en)	2015-12-22	2024-03-12	Regeneron Pharmaceuticals, Inc	USES OF A COMBINATION OF ANTI-PD-1 ANTIBODIES AND ANTI-CD20/ANTI-CD3 BIESPECIFIC ANTIBODIES AND OF A PHARMACEUTICAL COMPOSITION
CN106939047B (en)*	2016-01-04	2021-08-31	江苏怀瑜药业有限公司	PD-L1 antibody and preparation method thereof
US10596257B2 (en)	2016-01-08	2020-03-24	Hoffmann-La Roche Inc.	Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
CN105717298A (en)*	2016-01-29	2016-06-29	浙江数问生物技术有限公司	PD-L1 immunohistochemical kit
WO2017139755A1 (en)*	2016-02-12	2017-08-17	Rekoske Brian T	Cancer therapy
WO2017151502A1 (en)*	2016-02-29	2017-09-08	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
CN109476731A (en)	2016-02-29	2019-03-15	基础医药有限公司	Methods of treating cancer
US10143746B2 (en)	2016-03-04	2018-12-04	Bristol-Myers Squibb Company	Immunomodulators
CN107151269B (en)	2016-03-04	2021-07-27	四川科伦博泰生物医药股份有限公司	PDL-1 antibody, pharmaceutical composition and application thereof
JP7080213B2 (en)*	2016-03-23	2022-06-03	スーチョウトランセンタセラピューティクスカンパニー，リミテッド	New anti-PD-L1 antibody
US10613092B2 (en)	2016-04-01	2020-04-07	Agilent Technologies, Inc.	Scoring methods for anti-PD therapy eligibility and compositions for performing same
US10358463B2 (en)	2016-04-05	2019-07-23	Bristol-Myers Squibb Company	Immunomodulators
PL3443350T3 (en)*	2016-04-15	2021-05-31	F. Hoffmann-La Roche Ag	Methods for monitoring and treating cancer
TW202408578A (en)	2016-05-13	2024-03-01	美商再生元醫藥公司	Methods of treating skin cancer by administering a pd-1 inhibitor
DE102016005947B3 (en)*	2016-05-16	2017-06-08	Dimo Dietrich	A method for estimating the prognosis and predicting the response to immunotherapy of patients with malignant diseases
EP3458608A1 (en)*	2016-05-17	2019-03-27	H. Hoffnabb-La Roche Ag	Stromal gene signatures for diagnosis and use in immunotherapy
SI3458111T1 (en)	2016-05-19	2021-07-30	Bristol-Myers Squibb Company	Pet-imaging immunomodulators
JP6781252B2 (en)*	2016-06-10	2020-11-04	公益財団法人がん研究会	Multiple staining method and staining kit
KR102444170B1 (en)	2016-06-27	2022-09-16	예다 리서치 앤드 디벨럽먼트 캄파니 리미티드	Beto cells generated from memory T cells
CN109843931A (en)*	2016-08-11	2019-06-04	昆士兰医学研究所理事会	Immunomodulatory compounds
CN106198984B (en)*	2016-08-22	2019-07-05	上海立闻生物科技有限公司	The detection method of Peripheral Blood of Patients with Non-small Cell Lung circulating tumor cell PDL1 gene
WO2018057506A1 (en)*	2016-09-20	2018-03-29	Medimmune, Llc	Compositions and methods for characterizing solid tumors responsiveness to anti-pd-l1 antibody monotherapy
CN109843324A (en)	2016-10-06	2019-06-04	辉瑞公司	AVELUMAB therapeutic regimen for treating cancer
TWI775781B (en)	2016-10-06	2022-09-01	美商建南德克公司	Therapeutic and diagnostic methods for cancer
EP3535298B1 (en)	2016-11-02	2021-09-08	Jounce Therapeutics, Inc.	Antibodies to pd-1 and uses thereof
ES2910832T3 (en)	2016-11-07	2022-05-13	Bristol Myers Squibb Co	Immunomodulators
AU2017375946A1 (en)*	2016-12-12	2019-06-20	Genentech, Inc.	Methods of treating cancer using anti-PD-l1 antibodies and antiandrogens
EP3564678A4 (en)*	2016-12-28	2020-08-12	Kinki University	PROCEDURE FOR SELECTION OF PERSONS FOR ADMINISTRATION OF AN IMMUNCHECKPOINT INHIBITOR
AU2018211064A1 (en)*	2017-01-18	2019-09-05	Genentech, Inc.	Idiotypic antibodies against anti-PD-L1 antibodies and uses thereof
JP7162600B2 (en)*	2017-02-06	2022-10-28	ノヴァルティスアーゲー	Methods of Predicting Response to Immunotherapy
CA3052670A1 (en)	2017-03-01	2018-09-07	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
IL269026B2 (en)	2017-03-31	2024-12-01	Bristol Myers Squibb Co	Anti-PD-1 antibodies for the treatment of tumors in patients with high tumor mutational burden (TMB)
US11603407B2 (en)	2017-04-06	2023-03-14	Regeneron Pharmaceuticals, Inc.	Stable antibody formulation
WO2018191660A1 (en)*	2017-04-14	2018-10-18	Genentech, Inc.	Diagnostic and therapeutic methods for cancer
JP2020517913A (en)	2017-04-28	2020-06-18	ファイブプライムセラピューティクス，インコーポレイテッド	Method of treatment with CD80 extracellular domain polypeptide
EP3624800A4 (en)	2017-05-16	2021-02-17	Eisai R&D Management Co., Ltd.	Treatment of hepatocellular carcinoma
KR20200016899A (en)	2017-06-01	2020-02-17	싸이톰스 테라퓨틱스, 인크.	Activatable anti-PDL1 antibody, and methods of using the same
CA3066053A1 (en)*	2017-06-04	2018-12-13	Rappaport Family Institute For Research In The Medical Sciences	Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
US12016900B2 (en)	2017-06-04	2024-06-25	Rappaport Family Institute For Research In The Medical Sciences	Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
US12070489B2 (en)	2018-12-12	2024-08-27	Rappaport Family Institute For Research In The Medical Sciences	Method of treating cancer with a cancer therapy in combination with another therapeutic agent
SG10201911680SA (en)*	2017-06-13	2020-02-27	Bostongene Corp	Systems and methods for generating, visualizing and classifying molecular functional profiles
KR102735038B1 (en)	2017-06-23	2024-11-28	브리스톨-마이어스 스큅 컴퍼니	Immunomodulatory agent that acts as an antagonist of PD-1
US10636512B2 (en)	2017-07-14	2020-04-28	Cofactor Genomics, Inc.	Immuno-oncology applications using next generation sequencing
CN111492245A (en)*	2017-07-21	2020-08-04	基因泰克公司	Methods of treatment and diagnosis of cancer
CN111051332B (en)	2017-10-03	2024-09-06	百时美施贵宝公司	Immunomodulators
KR101982001B1 (en)*	2017-10-13	2019-05-27	한국과학기술원	Method for selecting of anti-pd-1 or anti-pd-l1 antibodies using alloimmunity or xenoimmunity
CN111247169A (en)	2017-10-15	2020-06-05	百时美施贵宝公司	Method for treating tumors
CN111566484A (en)	2017-11-09	2020-08-21	宾夕法尼亚大学董事会	Extracellular vesicle proteins and their use in cancer diagnosis, prediction of response to therapy, and treatment
CN111670364B (en)*	2017-11-30	2024-02-02	新加坡保健服务集团有限公司	Systems and methods for classifying cancer patients into an appropriate cancer treatment group and compositions for treating cancer patients
CN108179134B (en)*	2017-12-27	2020-11-24	武汉大学	Functionalized microfluidic chip based on EpCAM/PSMA double antibody and its preparation method and application
AU2019206958A1 (en)*	2018-01-10	2020-07-16	Jiangsu Hengrui Medicine Co., Ltd.	PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CA3089018A1 (en)*	2018-01-18	2019-07-25	Eutropics Pharmaceuticals, Inc.	Methods for predicting cancer drug responsiveness
KR102089241B1 (en)*	2018-02-05	2020-03-16	한국과학기술원	A method for prediction of the immunotherapy effects to cancer patients
EP3754031A4 (en)*	2018-02-14	2021-11-10	National University Corporation Tokai National Higher Education and Research System	BIOMARKERS FOR PREDICTING THE EFFECTS OF ANTI-PD-1 ANTIBODY / ANTI-PD-L1 ANTIBODY THERAPY
MX2020008882A (en)*	2018-02-26	2021-01-08	Genentech Inc	Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies.
WO2019169145A1 (en)*	2018-02-28	2019-09-06	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
US20190302124A1 (en)*	2018-03-27	2019-10-03	Laboratory Corporation Of America Holdings	Compositions and Methods for Identifying Subjects Who May Benefit From Treatment With Therapeutic Agents
WO2019222075A1 (en)*	2018-05-14	2019-11-21	Merck Sharp And Dohme Corp.	Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist
MY205645A (en)*	2018-06-23	2024-11-02	Genentech Inc	Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
KR102091637B1 (en)*	2018-07-10	2020-03-20	연세대학교 산학협력단	Methods for poviding information about responses to cancer immunotherapy and kits using the same
CN109116032B (en)*	2018-08-01	2021-09-03	广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院）	Kit for detecting PD-L1 antibody immunotherapy and prognosis of prostate cancer patient
KR102084196B1 (en)*	2018-08-29	2020-03-03	연세대학교 산학협력단	Methods for providing information about responses to cancer immunotherapy and kits using the same
JP2022501332A (en)	2018-09-19	2022-01-06	ジェネンテック，インコーポレイテッド	How to treat and diagnose bladder cancer
KR20210079311A (en)*	2018-10-18	2021-06-29	제넨테크, 인크.	Diagnosis and treatment methods for sarcoma renal cancer
KR102195135B1 (en)*	2018-12-07	2020-12-24	한국과학기술원	A screening method of immunomodulators
US20220081724A1 (en)*	2018-12-19	2022-03-17	Strata Oncology, Inc.	Methods of detecting and treating subjects with checkpoint inhibitor-responsive cancer
KR102159538B1 (en)*	2019-01-11	2020-09-24	충남대학교 산학협력단	IL-6 marker for predicting treatment response of a patient with lung cancer to cancer immunotherapy and uses thereof
CN109596831B (en)*	2019-01-14	2020-05-29	臻悦生物科技江苏有限公司	Multiple immunohistochemical analysis kit for lung cancer and use method and application thereof
WO2020172592A1 (en)*	2019-02-22	2020-08-27	Mitra Rxdx, Inc.	A method to predict a patient's response to an anti-cancer drug from a ratio of expression levels of two sets of genes
CN113166815B (en)*	2019-02-22	2024-06-11	深圳华大生命科学研究院	Use of intestinal metagenome in screening PD-1 antibody blocking agent curative effect
CN113678289B (en)	2019-03-27	2024-09-24	住友金属矿山株式会社	Positive electrode active material for lithium ion secondary battery, method for producing the same, and lithium ion secondary battery
CN109884303B (en)*	2019-03-29	2020-05-29	臻悦生物科技江苏有限公司	Multiple immunohistochemical analysis kit for liver cancer and use method and application thereof
US20200365249A1 (en)*	2019-05-15	2020-11-19	Micareo Taiwan Co., Ltd.	Methods for predicting immunotherapy response of subject having cancer
CN110687281B (en)*	2019-08-26	2023-05-23	中国医学科学院肿瘤医院	Application of PD-L1 autoantibody in tumor prognosis evaluation
US20210088523A1 (en)*	2019-09-23	2021-03-25	Sri International	Methods for detecting circulating tumor cells in non-small cell lung cancer
AU2020372333A1 (en)*	2019-10-21	2022-04-28	Celgene Corporation	Methods for treating a hematological cancer and the use of companion biomarkers for 2-(2,6-Dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione
CN110927389B (en)*	2019-11-29	2021-07-16	中国科学院苏州生物医学工程技术研究所	A cancer biomarker, use
KR102371903B1 (en)*	2019-12-24	2022-03-08	주식회사 테라젠바이오	Methods for poviding information about responses to cancer immunotherapy and devices using the same
WO2021202959A1 (en)*	2020-04-03	2021-10-07	Genentech, Inc.	Therapeutic and diagnostic methods for cancer
CN111521796A (en)*	2020-04-21	2020-08-11	山东第一医科大学(山东省医学科学院)	Immunofluorescence kit and detection method for detecting expression of peripheral blood circulating tumor cells PD-L1 of renal cancer patient
CN111521792A (en)*	2020-04-21	2020-08-11	山东第一医科大学(山东省医学科学院)	Immunofluorescence kit and method for detecting PD-L1 gene mutation in peripheral blood circulating tumor cells of patients with non-small cell lung cancer
CN115885050A (en)	2020-04-28	2023-03-31	基因泰克公司	Methods and compositions for non-small cell lung cancer immunotherapy
WO2021228888A1 (en)	2020-05-12	2021-11-18	Asylia Diagnostics	Biomarkers for hyperprogressive disease and therapy response after immunotherapy
CN111863126B (en)*	2020-05-28	2024-03-26	上海市生物医药技术研究院	Method for constructing colorectal tumor state evaluation model and application
JP2023529026A (en)*	2020-06-01	2023-07-06	デイナファーバーキャンサーインスティチュート，インコーポレイテッド	Methods for modulating MHC-I expression and immunotherapeutic uses thereof - Patents.com
WO2022135402A1 (en)*	2020-12-24	2022-06-30	信达生物制药(苏州)有限公司	Use of pd-l1 and/or mhc-2 biomarker in prediction of therapeutic efficacy in lung cancer patients
RU2766739C1 (en)*	2021-04-12	2022-03-15	Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России)	Method for prediction of clinical effectiveness in melanoma
CN113109565B (en)*	2021-04-12	2024-02-02	中国人民解放军空军军医大学	Detection box for evaluating sensitivity of patient to PD-1 monoclonal antibody product and application thereof
CN113358872B (en)*	2021-06-03	2022-10-21	中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所）	Marker panel and system for evaluating the efficacy of tumor immunotherapy
US20240336971A1 (en)	2021-07-22	2024-10-10	Asylia Diagnostics Bv	Biomarkers for Therapy Response After Immunotherapy
AU2022327751A1 (en)	2021-08-11	2024-03-21	OncoHost Ltd.	Predicting patient response
CN114022472B (en)*	2021-11-17	2022-05-20	深圳裕策生物科技有限公司	Tumor infiltrating lymphocyte analysis method, device and storage medium
AU2023305322A1 (en)*	2022-07-14	2025-02-27	Central Adelaide Local Health Network Inc	Methods and products for determining responsiveness to anti-pd1 immune checkpoint inhibitor immunotherapy
CN117701719B (en)*	2024-02-04	2024-05-31	北京肿瘤医院(北京大学肿瘤医院)	Tumor targeting CLDN18.2 therapeutic drug-resistant marker and application thereof
CN117741148B (en)*	2024-02-19	2024-06-14	苏州颐坤生物科技有限公司	Marker combination for predicting curative effect of immunotherapy and model construction method and application

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4018653A (en)	1971-10-29	1977-04-19	U.S. Packaging Corporation	Instrument for the detection of Neisseria gonorrhoeae without culture
US4016043A (en)	1975-09-04	1977-04-05	Akzona Incorporated	Enzymatic immunological method for the determination of antigens and antibodies
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4318980A (en)	1978-04-10	1982-03-09	Miles Laboratories, Inc.	Heterogenous specific binding assay employing a cycling reactant as label
US4424279A (en)	1982-08-12	1984-01-03	Quidel	Rapid plunger immunoassay method and apparatus
WO1984003506A1 (en)	1983-03-08	1984-09-13	Commw Serum Lab Commission	Antigenically active amino acid sequences
EP0138854B1 (en)	1983-03-08	1992-11-04	Chiron Mimotopes Pty. Ltd.	Antigenically active amino acid sequences
NZ207394A (en)	1983-03-08	1987-03-06	Commw Serum Lab Commission	Detecting or determining sequence of amino acids
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3590766C2 (en)	1985-03-30	1991-01-10	Marc Genf/Geneve Ch Ballivet
NZ215865A (en)	1985-04-22	1988-10-28	Commw Serum Lab Commission	Method of determining the active site of a receptor-binding analogue
US4737456A (en)	1985-05-09	1988-04-12	Syntex (U.S.A.) Inc.	Reducing interference in ligand-receptor binding assays
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5763192A (en)	1986-11-20	1998-06-09	Ixsys, Incorporated	Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
US5606040A (en)	1987-10-30	1997-02-25	American Cyanamid Company	Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en)	1987-10-30	1998-06-23	American Cyanamid Company	Process for preparing targeted forms of methyltrithio antitumor agents
US5266684A (en)	1988-05-02	1993-11-30	The Reagents Of The University Of California	Peptide mixtures
US5571689A (en)	1988-06-16	1996-11-05	Washington University	Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
US5663143A (en)	1988-09-02	1997-09-02	Dyax Corp.	Engineered human-derived kunitz domains that inhibit human neutrophil elastase
EP0368684B2 (en)	1988-11-11	2004-09-29	Medical Research Council	Cloning immunoglobulin variable domain sequences.
DE3920358A1 (en)	1989-06-22	1991-01-17	Behringwerke Ag	BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
CA2026147C (en)	1989-10-25	2006-02-07	Ravi J. Chari	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5498538A (en)	1990-02-15	1996-03-12	The University Of North Carolina At Chapel Hill	Totally synthetic affinity reagents
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
US5723286A (en)	1990-06-20	1998-03-03	Affymax Technologies N.V.	Peptide library and screening systems
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5770434A (en)	1990-09-28	1998-06-23	Ixsys Incorporated	Soluble peptides having constrained, secondary conformation in solution and method of making same
US5698426A (en)	1990-09-28	1997-12-16	Ixsys, Incorporated	Surface expression libraries of heteromeric receptors
DE69130831T2 (en)	1990-11-21	1999-09-16	Iterex Pharmaceuticals Ltd. Partnership, San Diego	SYNTHESIS OF EQUIMOLAR MIXTURES OF VARIOUS OLIGOMERS, SPECIALLY OLIGOPEPTIDE MIXTURES
CA2095633C (en)	1990-12-03	2003-02-04	Lisa J. Garrard	Enrichment method for variant proteins with altered binding properties
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
WO1992022653A1 (en)	1991-06-14	1992-12-23	Genentech, Inc.	Method for making humanized antibodies
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
US5587458A (en)	1991-10-07	1996-12-24	Aronex Pharmaceuticals, Inc.	Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5270170A (en)	1991-10-16	1993-12-14	Affymax Technologies N.V.	Peptide library and screening method
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
CA2372813A1 (en)	1992-02-06	1993-08-19	L.L. Houston	Biosynthetic binding protein for cancer marker
ATE196606T1 (en)	1992-11-13	2000-10-15	Idec Pharma Corp	THERAPEUTIC USE OF CHIMERIC AND LABELED ANTIBODIES DIRECTED AGAINST A DIFFERENTIATION ANTIGEN WHICH EXPRESSION IS RESTRICTED TO HUMAN B LYMPHOCYTES, FOR THE TREATMENT OF B-CELL LYMPHOMA
US5635483A (en)	1992-12-03	1997-06-03	Arizona Board Of Regents Acting On Behalf Of Arizona State University	Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en)	1993-01-26	1998-07-14	Arizona Board Of Regents	Elucidation and synthesis of selected pentapeptides
CA2163345A1 (en)	1993-06-16	1994-12-22	Susan Adrienne Morgan	Antibodies
US5922855A (en)	1993-12-17	1999-07-13	Oregon Health Sciences University	Mammalian DNA mismatch repair genes MLH1 and PMS1
US5773001A (en)	1994-06-03	1998-06-30	American Cyanamid Company	Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
WO1995034683A1 (en)	1994-06-10	1995-12-21	Symbiotech, Inc.	Method of detecting compounds utilizing genetically modified lambdoid bacteriophage
US5627024A (en)	1994-08-05	1997-05-06	The Scripps Research Institute	Lambdoid bacteriophage vectors for expression and display of foreign proteins
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US5714586A (en)	1995-06-07	1998-02-03	American Cyanamid Company	Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en)	1995-06-07	1998-01-27	American Cyanamid Company	Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US6267958B1 (en)	1995-07-27	2001-07-31	Genentech, Inc.	Protein formulation
ATE239799T1 (en)	1995-09-07	2003-05-15	Novozymes As	DETECTION OF DETERGENT ENZYME ACTIVITY BY PHAGES.
GB9603256D0 (en)	1996-02-16	1996-04-17	Wellcome Found	Antibodies
IL126045A0 (en)	1996-03-20	1999-05-09	Dyax Corp	Purification of tissue plasminogen activator (tpa)
EP0954531A1 (en)	1996-06-06	1999-11-10	Lajolla Pharmaceutical Company	aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
DE69731226T2 (en)	1996-06-10	2006-03-09	The Scripps Research Institute, La Jolla	USE OF SUBSTRATE SUBTRACTION LIBRARIES FOR THE DISTINCTION OF ENZYME SPECIFICATIONS
US5766905A (en)	1996-06-14	1998-06-16	Associated Universities Inc.	Cytoplasmic bacteriophage display system
WO1998014277A1 (en)	1996-10-04	1998-04-09	Whatman, Inc.	Device and method for simultaneous multiple chemical syntheses
CA2267139A1 (en)	1996-10-08	1998-04-16	Ton Logtenberg	Methods and means for selecting peptides and proteins having specific affinity for a target
AU745101B2 (en)	1996-11-06	2002-03-14	Genentech Inc.	Constrained helical peptides and methods of making same
IL119586A (en)	1996-11-07	2001-09-13	Univ Ramot	Discontinuous library of a single biological unit and a method for its preparation
IL119587A (en)	1996-11-07	2000-12-06	Univ Ramot	Method of preparing and for obtaining bimolecular interactions
US6171586B1 (en)	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
PT994903E (en)	1997-06-24	2005-10-31	Genentech Inc	METHODS AND COMPOSITIONS FOR GALACTOSILED GLICOPROTEINS
EP1025220B1 (en)	1997-10-21	2007-01-03	The University Court Of The University Of Glasgow	JMY, A CO-ACTIVATOR FOR p300/CBP, NUCLEIC ACID ENCODING JMY AND USES THEREOF
WO1999022764A1 (en)	1997-10-31	1999-05-14	Genentech, Inc.	Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
ES2375931T3 (en)	1997-12-05	2012-03-07	The Scripps Research Institute	HUMANIZATION OF ANTIBODY MURINO.
US6194551B1 (en)	1998-04-02	2001-02-27	Genentech, Inc.	Polypeptide variants
WO1999051642A1 (en)	1998-04-02	1999-10-14	Genentech, Inc.	Antibody variants and fragments thereof
AU3657899A (en)	1998-04-20	1999-11-08	James E. Bailey	Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6335155B1 (en)	1998-06-26	2002-01-01	Sunesis Pharmaceuticals, Inc.	Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
CA2355215A1 (en)	1998-12-28	2000-07-06	Jim Wells	Identifying small organic molecule ligands for binding
HUP0104865A3 (en)	1999-01-15	2004-07-28	Genentech Inc	Polypeptide variants with altered effector function
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
EP3031917A1 (en)	1999-04-09	2016-06-15	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
DE60033293D1 (en)	1999-08-23	2007-03-22	Dana Farber Cancer Inst Inc	NEW B7-4 MOLECULES AND THEIR USES
JP4668498B2 (en)	1999-10-19	2011-04-13	協和発酵キリン株式会社	Method for producing polypeptide
US6803192B1 (en)	1999-11-30	2004-10-12	Mayo Foundation For Medical Education And Research	B7-H1, a novel immunoregulatory molecule
PT1234031T (en)	1999-11-30	2017-06-26	Mayo Foundation	B7-h1, a novel immunoregulatory molecule
IL149809A0 (en)	1999-12-15	2002-11-10	Genentech Inc	Shotgun scanning, a combinatorial method for mapping functional protein epitopes
JP2003531821A (en)	1999-12-29	2003-10-28	イムノージェンインコーポレーテッド	Cytotoxic drugs containing modified doxorubicin and daunorubicin and their therapeutic use
HUP0300369A2 (en)	2000-04-11	2003-06-28	Genentech, Inc.	Multivalent antibodies and uses therefor
US7064191B2 (en)	2000-10-06	2006-06-20	Kyowa Hakko Kogyo Co., Ltd.	Process for purifying antibody
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
WO2002031140A1 (en)	2000-10-06	2002-04-18	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
CA2430013C (en)	2000-11-30	2011-11-22	Medarex, Inc.	Transgenic transchromosomal rodents for making human antibodies
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
NZ581474A (en)	2001-08-03	2011-04-29	Glycart Biotechnology Ag	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
ATE430580T1 (en)	2001-10-25	2009-05-15	Genentech Inc	GLYCOPROTEIN COMPOSITIONS
US20040093621A1 (en)	2001-12-25	2004-05-13	Kyowa Hakko Kogyo Co., Ltd	Antibody composition which specifically binds to CD20
US20040259150A1 (en)	2002-04-09	2004-12-23	Kyowa Hakko Kogyo Co., Ltd.	Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
EP1502603A4 (en)	2002-04-09	2006-12-13	Kyowa Hakko Kogyo Kk	DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM Fc gamma RIIIa POLYMORPHISM
CA2481920A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Antibody composition-containing medicament
ES2362419T3 (en)	2002-04-09	2011-07-05	Kyowa Hakko Kirin Co., Ltd.	CELLS WITH DEPRESSION OR DELETION OF THE ACTIVITY OF THE PROTEIN THAT PARTICIPATES IN THE TRANSPORT OF GDP-FUCOSA.
WO2003085118A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Process for producing antibody composition
MXPA04009924A (en)	2002-04-09	2005-07-01	Kyowa Hakko Kogyo Kk	Cells with modified genome.
CA2488441C (en)	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
DK1388734T3 (en)*	2002-08-01	2004-05-03	Mtm Lab Ag	Method for solution-based diagnosis
US7361740B2 (en)	2002-10-15	2008-04-22	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
PL212899B1 (en)	2002-12-16	2012-12-31	Genentech Inc	Immunoglobulin variants and uses thereof
CA2510003A1 (en)	2003-01-16	2004-08-05	Genentech, Inc.	Synthetic antibody phage libraries
US7871607B2 (en)	2003-03-05	2011-01-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en)	2003-03-05	2006-05-18	Halozyme, Inc.	Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
WO2005035586A1 (en)	2003-10-08	2005-04-21	Kyowa Hakko Kogyo Co., Ltd.	Fused protein composition
AU2004280065A1 (en)	2003-10-09	2005-04-21	Kyowa Hakko Kirin Co., Ltd.	Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase
MX337587B (en)	2003-11-05	2016-03-11	Glycart Biotechnology Ag	Antigen binding molecules with increased fc receptor binding affinity and effector function.
SG10201701737XA (en)	2003-11-06	2017-04-27	Seattle Genetics Inc	Monomethylvaline compounds capable of conjugation to ligands
WO2005053742A1 (en)	2003-12-04	2005-06-16	Kyowa Hakko Kogyo Co., Ltd.	Medicine containing antibody composition
US7527791B2 (en)	2004-03-31	2009-05-05	Genentech, Inc.	Humanized anti-TGF-beta antibodies
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
EP2357201B1 (en)	2004-04-13	2017-08-30	F. Hoffmann-La Roche AG	Anti-P-selectin antibodies
AU2012211347B9 (en)*	2004-07-20	2015-06-18	Alexion Pharmaceuticals, Inc.	Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
TWI309240B (en)	2004-09-17	2009-05-01	Hoffmann La Roche	Anti-ox40l antibodies
ES2669510T3 (en)	2004-09-23	2018-05-28	Genentech, Inc.	Antibodies and conjugates engineered with cysteine
CN101084438B (en)*	2004-10-06	2013-12-25	梅约医学教育与研究基金会	B7-H1 and methods of diagnosis, prognosis, and treatment of cancer
PL3428191T3 (en)	2004-10-06	2025-04-07	Mayo Foundation For Medical Education And Research	B7-H1 and PD-1 in the treatment of renal cell carcinoma
JO3000B1 (en)	2004-10-20	2016-09-05	Genentech Inc	Antibody Formulations.
RU2494107C2 (en)	2005-05-09	2013-09-27	Оно Фармасьютикал Ко., Лтд.	Human monoclonal antibodies specific for programmed cell death 1 (pd1) protein and methods of treating cancer with using anti-pd1 antibodies either individually, or in combination with other immunotherapeutic agents
EP3130350A1 (en)*	2005-06-08	2017-02-15	Dana-Farber Cancer Institute, Inc.	Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway
KR101888321B1 (en)	2005-07-01	2018-08-13	이. 알. 스퀴부 앤드 선즈, 엘.엘.씨.	Human monoclonal antibodies to programmed death ligand 1(pd-l1)
EP1777523A1 (en)*	2005-10-19	2007-04-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
US20090221010A1 (en)	2005-10-21	2009-09-03	Elting James J	Methods for Prediction and Prognosis of Cancer, and Monitoring Cancer Therapy
EP1957531B1 (en)	2005-11-07	2016-04-13	Genentech, Inc.	Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
WO2007064919A2 (en)	2005-12-02	2007-06-07	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
WO2007082154A2 (en)	2006-01-05	2007-07-19	Mayo Foundation For Medical Education And Research	B7-h1 and b7-h4 in cancer
US20100015642A1 (en)*	2006-01-05	2010-01-21	Kwon Eugene D	B7-h1 and survivin in cancer
EP2468765B1 (en)	2006-03-03	2015-04-22	ONO Pharmaceutical Co., Ltd.	Tetramer of extracellular domain of PD-L1
AR060871A1 (en)	2006-05-09	2008-07-16	Genentech Inc	UNION OF POLYPEPTIDES WITH OPTIMIZED SUPERCONTIGES
CN101104640A (en)	2006-07-10	2008-01-16	苏州大学	Preparation and application of anti-human PD-L1 monoclonal antibody
US7895540B2 (en)	2006-08-02	2011-02-22	Georgia Tech Research Corporation	Multilayer finite difference methods for electrical modeling of packages and printed circuit boards
US20080226635A1 (en)	2006-12-22	2008-09-18	Hans Koll	Antibodies against insulin-like growth factor I receptor and uses thereof
EP2126575A2 (en)*	2007-02-28	2009-12-02	The Procter & Gamble	Methods and targets for identifying compounds for regulating rhinovirus infection
CN100592373C (en)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	Liquid crystal panel drive device and its drive method
DK2235064T3 (en)	2008-01-07	2016-01-11	Amgen Inc	A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
MX349463B (en)	2008-09-26	2017-07-31	Univ Emory	Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor.
WO2010056735A1 (en)*	2008-11-11	2010-05-20	The Trustees Of The University Of Pennsylvania	Compositions and methods for inhibiting an oncogenic protein to enhance immunogenicity
SG196798A1 (en)	2008-12-09	2014-02-13	Genentech Inc	Anti-pd-l1 antibodies and their use to enhance t-cell function
US8741295B2 (en)	2009-02-09	2014-06-03	Universite De La Mediterranee	PD-1 antibodies and PD-L1 antibodies and uses thereof
EP2404997B1 (en)	2009-03-06	2017-10-18	Mie University	Method for enhancing t cell function
EP3375791A1 (en)*	2009-09-30	2018-09-19	Memorial Sloan Kettering Cancer Center	Combination immunotherapy for the treatment of cancer
HUE037159T2 (en)	2009-11-24	2018-08-28	Medimmune Ltd	Targeted Binding Agents Against B7-H1
US20130109019A1 (en)	2010-07-02	2013-05-02	Adrian E. Murillo	Hapten conjugates for target detection
US20120010230A1 (en)*	2010-07-08	2012-01-12	Macdougall John R	Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
SG187886A1 (en)*	2010-08-31	2013-04-30	Genentech Inc	Biomarkers and methods of treatment
EP2975399B1 (en)*	2010-09-15	2022-05-11	Almac Diagnostic Services Limited	Molecular diagnostic test for cancer
EP3403672A1 (en)*	2011-04-20	2018-11-21	Medlmmune, LLC	Antibodies and other molecules that bind b7-h1 and pd-1
CN102250911A (en)*	2011-05-31	2011-11-23	苏州大学	Soluble B7-H1 quantitative detection kit
BR112014002353B1 (en)*	2011-08-01	2022-09-27	Genentech, Inc	USES OF PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND KIT
SI2785375T1 (en)	2011-11-28	2020-11-30	Merck Patent Gmbh	Anti-pd-l1 antibodies and uses thereof
WO2013172926A1 (en)	2012-05-14	2013-11-21	Yale University	Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer
BR112014028826B1 (en)*	2012-05-15	2024-04-30	Bristol-Myers Squibb Company	USE OF NIVOLUMAB OR PEMBROLIZUMAB
WO2013173233A1 (en)	2012-05-17	2013-11-21	Baker Hughes Incorporated	Dendritic surfactants and extended surfactants for drilling fluid formulations
JP6403166B2 (en)	2012-08-03	2018-10-10	ダナ−ファーバーキャンサーインスティテュート，インコーポレイテッド	Single antigen anti-PD-L1 and PD-L2 double-binding antibodies and methods of use thereof
EP3446709A1 (en)	2012-08-07	2019-02-27	F. Hoffmann-La Roche AG	Combination therapy for the treatment of glioblastoma
EP3511718A1 (en)	2012-11-30	2019-07-17	F. Hoffmann-La Roche AG	Pd-l1 inhibitor
AR093984A1 (en)	2012-12-21	2015-07-01	Merck Sharp & Dohme	ANTIBODIES THAT JOIN LEGEND 1 OF SCHEDULED DEATH (PD-L1) HUMAN
WO2014165082A2 (en)	2013-03-13	2014-10-09	Medimmune, Llc	Antibodies and methods of detection
US20150071910A1 (en)	2013-03-15	2015-03-12	Genentech, Inc.	Biomarkers and methods of treating pd-1 and pd-l1 related conditions
CA3180286A1 (en)	2013-03-15	2014-09-25	Genentech, Inc.	Biomarkers and methods of treating pd-1 and pd-l1 related conditions
EP2981821B2 (en)	2013-04-02	2021-11-03	Merck Sharp & Dohme Corp.	Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
WO2014194293A1 (en)	2013-05-30	2014-12-04	Amplimmune, Inc.	Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
CA2919473A1 (en)	2013-07-24	2015-01-29	Dana-Farber Cancer Institute, Inc.	Anti-galectin-1 monoclonal antibodies and fragments thereof
GB201316027D0 (en)	2013-09-09	2013-10-23	Almac Diagnostics Ltd	Molecular diagnostic test for oesophageal cancer
GB201316024D0 (en)	2013-09-09	2013-10-23	Almac Diagnostics Ltd	Molecular diagnostic test for lung cancer
WO2015038538A1 (en)	2013-09-10	2015-03-19	Medimmune, Llc	Compositions and methods for treating sepsis
MX370818B (en)	2013-09-11	2020-01-08	Medimmune Ltd	Anti-b7-h1 antibodies for treating tumors.
AU2014339900B2 (en)	2013-10-25	2019-10-24	Dana-Farber Cancer Institute, Inc.	Anti-PD-L1 monoclonal antibodies and fragments thereof
EP3079772B1 (en)	2013-12-10	2020-02-05	Merck Sharp & Dohme Corp.	Immunohistochemical proximity assay for pd-1 positive cells and pd-ligand positive cells in tumor tissue
CA2940439C (en)	2014-02-24	2024-03-19	Ventana Medical Systems, Inc.	Quinone methide analog signal amplification
US20150322184A1 (en)	2014-05-07	2015-11-12	Chevron Phillips Chemical Company Lp	High Performance Moisture Barrier Films at Lower Densities
JP2017514967A (en)	2014-05-12	2017-06-08	ザプロクターアンドギャンブルカンパニー	Antibacterial cleaning composition
US9885721B2 (en)	2014-05-29	2018-02-06	Spring Bioscience Corporation	PD-L1 antibodies and uses thereof
EP3149481B1 (en)	2014-05-30	2019-01-09	Ventana Medical Systems, Inc.	Multiplex assay for improved scoring of tumor tissues stained for pd-l1
DK3309174T3 (en)	2014-07-11	2022-06-07	Ventana Med Syst Inc	ANTI-PD-L1 antibodies and diagnostic uses thereof

2014
- 2014-03-12CACA3180286Apatent/CA3180286A1/enactivePending
- 2014-03-12NZNZ751260Apatent/NZ751260A/enunknown
- 2014-03-12KRKR1020227012872Apatent/KR20220053691A/ennot_activeCeased
- 2014-03-12CACA2905798Apatent/CA2905798C/enactiveActive
- 2014-03-12MYMYPI2015002278Apatent/MY176706A/enunknown
- 2014-03-12SGSG11201507333XApatent/SG11201507333XA/enunknown
- 2014-03-12PLPL14714119Tpatent/PL2972373T3/enunknown
- 2014-03-12KRKR1020237015323Apatent/KR20230070054A/ennot_activeCeased
- 2014-03-12EPEP19191154.4Apatent/EP3633377A1/ennot_activeWithdrawn
- 2014-03-12EPEP14714119.6Apatent/EP2972373B1/enactiveActive
- 2014-03-12MXMX2015011774Apatent/MX374488B/enactiveIP Right Grant
- 2014-03-12WOPCT/US2014/024746patent/WO2014151006A2/enactiveApplication Filing
- 2014-03-12MYMYPI2018000698Apatent/MY197809A/enunknown
- 2014-03-12JPJP2016501626Apatent/JP6483082B2/enactiveActive
- 2014-03-12ESES14714119Tpatent/ES2761260T3/enactiveActive
- 2014-03-12KRKR1020157029278Apatent/KR20150131269A/ennot_activeCeased
- 2014-03-12BRBR112015023120Apatent/BR112015023120A2/enactiveSearch and Examination
- 2014-03-12NZNZ712314Apatent/NZ712314A/enunknown
- 2014-03-12EPEP23217779.0Apatent/EP4356960A3/enactivePending
- 2014-03-12KRKR1020207026646Apatent/KR102389677B1/enactiveActive
- 2014-03-12KRKR1020247016699Apatent/KR20240093812A/ennot_activeCeased
- 2014-03-12CNCN201910113951.2Apatent/CN110079599B/enactiveActive
- 2014-03-12AUAU2014235453Apatent/AU2014235453A1/ennot_activeAbandoned
- 2014-03-12SGSG10201701380TApatent/SG10201701380TA/enunknown
- 2014-03-12NZNZ751264Apatent/NZ751264A/enunknown
- 2014-03-12RURU2015139224Apatent/RU2701378C2/enactive
- 2014-03-12KRKR1020187026186Apatent/KR102158924B1/enactiveActive
- 2014-03-12CNCN201480027406.7Apatent/CN105209919B/enactiveActive
- 2014-03-12ILIL318611Apatent/IL318611A/enunknown
- 2014-03-12CNCN202410595099.8Apatent/CN118547067A/enactivePending
2015
- 2015-09-07MXMX2020008976Apatent/MX2020008976A/enunknown
- 2015-09-08ILIL241309Apatent/IL241309B/enactiveIP Right Grant
- 2015-09-10USUS14/850,462patent/US11299544B2/enactiveActive
2016
- 2016-01-20HKHK16100590.6Apatent/HK1212769A1/enunknown
2017
- 2017-09-07AUAU2017225061Apatent/AU2017225061B2/enactiveActive
2018
- 2018-11-19JPJP2018216412Apatent/JP6845840B2/enactiveActive
2019
- 2019-11-26ILIL270943Apatent/IL270943A/enunknown
- 2019-11-26AUAU2019271922Apatent/AU2019271922C1/enactiveActive
2022
- 2022-03-04USUS17/686,628patent/US20220363764A1/enactivePending
- 2022-05-30AUAU2022203671Apatent/AU2022203671B2/enactiveActive
2025
- 2025-02-17AUAU2025201101Apatent/AU2025201101A1/enactivePending

Publication number	Publication date
CA2905798C (en)	2023-01-24
CA2905798A1 (en)	2014-09-25
AU2022203671A1 (en)	2022-06-16
NZ712314A (en)	2021-07-30
MX2020008976A (en)	2020-09-28
CN105209919B (en)	2019-03-05
IL270943A (en)	2020-01-30
RU2015139224A3 (en)	2018-03-12
IL318611A (en)	2025-03-01
JP2016520800A (en)	2016-07-14
CN105209919A (en)	2015-12-30
JP6483082B2 (en)	2019-03-13
AU2022203671B2 (en)	2024-11-28
BR112015023120A2 (en)	2017-11-21
PL2972373T3 (en)	2020-03-31
AU2017225061A1 (en)	2017-09-28
NZ751260A (en)	2021-07-30
EP4356960A3 (en)	2024-07-10
MY176706A (en)	2020-08-19
AU2019271922B2 (en)	2022-03-17
CN110079599A (en)	2019-08-02
CN118547067A (en)	2024-08-27
MY197809A (en)	2023-07-18
EP3633377A1 (en)	2020-04-08
CN110079599B (en)	2024-06-04
KR20180103192A (en)	2018-09-18
KR102389677B1 (en)	2022-04-21
JP2019060883A (en)	2019-04-18
KR102158924B1 (en)	2020-09-22
ES2761260T3 (en)	2020-05-19
US11299544B2 (en)	2022-04-12
SG10201701380TA (en)	2017-04-27
AU2017225061B2 (en)	2019-11-21
US20160222118A1 (en)	2016-08-04
MX2015011774A (en)	2015-12-01
KR20230070054A (en)	2023-05-19
KR20200109397A (en)	2020-09-22
IL241309B (en)	2019-12-31
NZ751264A (en)	2021-07-30
HK1212769A1 (en)	2016-06-17
WO2014151006A3 (en)	2014-11-27
AU2014235453A1 (en)	2015-10-08
AU2019271922C1 (en)	2022-11-24
JP6845840B2 (en)	2021-03-24
RU2701378C2 (en)	2019-09-26
CA3180286A1 (en)	2014-09-25
KR20220053691A (en)	2022-04-29
US20220363764A1 (en)	2022-11-17
KR20240093812A (en)	2024-06-24
EP2972373B1 (en)	2019-10-09
WO2014151006A2 (en)	2014-09-25
IL241309A0 (en)	2015-11-30
AU2019271922A1 (en)	2019-12-19
RU2015139224A (en)	2017-04-21
EP4356960A2 (en)	2024-04-24
KR20150131269A (en)	2015-11-24
MX374488B (en)	2025-03-06
EP2972373A2 (en)	2016-01-20
AU2025201101A1 (en)	2025-03-06

Publication	Publication Date	Title
HK1212769A1 (en)	2016-06-17	Biomarkers and methods of treating pd-1 and pd-l1 related conditions pd-1 pd-l1
ZA201800079B (en)	2022-07-27	Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
HK1218506A1 (en)	2017-02-24	Methods of treating melanoma
HK1219975A1 (en)	2017-04-21	Cell lines for virus production and methods of use
HK1217908A1 (en)	2017-01-27	Methods of treating cholangiocarcinoma
EP2970317A4 (en)	2016-11-02	Pyrimido-diazepinone compounds and methods of treating disorders
SG10201802772YA (en)	2018-05-30	Methods of detection and removal of rhabdoviruses from cell lines
GB2513304B (en)	2015-12-16	Peripheral apparatus and method of construction
EP3063310A4 (en)	2017-06-28	Method of treating metal surfaces
ZA201600927B (en)	2017-11-29	Structural assembly and method of assembly thereof
HK1223844A1 (en)	2017-08-11	Method for the management of cancer and treatment of cancer comorbidities
HK1212999A1 (en)	2016-06-24	Methods for treating and or limiting development of diabetes
HK1220453A1 (en)	2017-05-05	Methods of treating dyskinesia and related disorders
IL239909A0 (en)	2015-08-31	Methods of treating cardiovascular indications
HK1200093A1 (en)	2015-07-31	Methods of treating melanoma with pak1 inhibitors pak1
GB201910300D0 (en)	2019-09-04	Method of and apparatuses for indentifying geological characteristics
HK1222323A1 (en)	2017-06-30	Compositions and methods for treating conditions that affect epidermis
GB201321104D0 (en)	2014-01-15	Method and plant for treatment of dispersion
AU2013904630A0 (en)	2013-12-12	Method of treating melanoma

Movatterモバイル変換

SG11201507333XA - Biomarkers and methods of treating pd-1 and pd-l1 related conditions - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (5)

Publications (1)

Family

ID=50391526

Family Applications (2)

Family Applications After (1)

Country Status (18)

Families Citing this family (144)

Family Cites Families (183)

Also Published As

Similar Documents